Doximity [DOCS] vs HealthEquity [HQY] Detailed Stock Comparison
Doximity
NYSE
Loading...
HealthEquity
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Doximity wins in 11 metrics, HealthEquity wins in 8 metrics, with 0 ties. Doximity appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Doximity | HealthEquity | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 52.84 | 65.16 | Doximity |
| Price-to-Book Ratio | 11.30 | 3.64 | HealthEquity |
| Debt-to-Equity Ratio | 1.16 | 52.11 | Doximity |
| PEG Ratio | 51.95 | 24.19 | HealthEquity |
| EV/EBITDA | 44.08 | 21.05 | HealthEquity |
| Profit Margin (TTM) | 39.88% | 9.80% | Doximity |
| Operating Margin (TTM) | 37.48% | 25.50% | Doximity |
| EBITDA Margin (TTM) | 37.48% | 25.50% | Doximity |
| Return on Equity | 24.25% | 5.77% | Doximity |
| Return on Assets (TTM) | 13.13% | 4.57% | Doximity |
| Free Cash Flow (TTM) | $266.74M | $-165.60M | Doximity |
| 1-Year Return | 82.18% | 20.05% | Doximity |
| Price-to-Sales Ratio (TTM) | 19.64 | 6.21 | HealthEquity |
| Enterprise Value | $10.75B | $8.54B | Doximity |
| EV/Revenue Ratio | 18.23 | 6.87 | HealthEquity |
| Gross Profit Margin (TTM) | 89.18% | 67.80% | Doximity |
| Revenue per Share (TTM) | $3 | $14 | HealthEquity |
| Earnings per Share (Diluted) | $1.17 | $1.37 | HealthEquity |
| Beta (Stock Volatility) | 1.36 | 0.54 | HealthEquity |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Doximity vs HealthEquity Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Doximity | 2.50% | -2.18% | 4.96% | 11.43% | -16.42% | 21.60% |
| HealthEquity | 2.81% | -3.40% | -6.54% | -7.95% | -20.62% | -7.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Doximity | 82.18% | 97.30% | 16.35% | 16.35% | 16.35% | 16.35% |
| HealthEquity | 20.05% | 46.16% | 66.28% | 207.11% | 430.32% | 430.32% |
Performance & Financial Health Analysis: Doximity vs HealthEquity
| Metric | DOCS | HQY |
|---|---|---|
| Market Information | ||
| Market Cap | $11.58B | $7.72B |
| Market Cap Category | Large cap | Mid cap |
| 10 Day Avg. Volume | 2,390,453 | 981,810 |
| 90 Day Avg. Volume | 1,815,488 | 898,080 |
| Last Close | $65.13 | $89.89 |
| 52 Week Range | $34.34 - $85.21 | $71.33 - $116.65 |
| % from 52W High | -23.57% | -22.94% |
| All-Time High | $107.79 (Sep 06, 2021) | $116.65 (Jun 05, 2025) |
| % from All-Time High | -39.58% | -22.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.15% |
| Quarterly Earnings Growth | 0.29% | 0.87% |
| Financial Health | ||
| Profit Margin (TTM) | 0.40% | 0.10% |
| Operating Margin (TTM) | 0.37% | 0.26% |
| Return on Equity (TTM) | 0.24% | 0.06% |
| Debt to Equity (MRQ) | 1.16 | 52.11 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.47 | $24.49 |
| Cash per Share (MRQ) | $4.49 | $3.33 |
| Operating Cash Flow (TTM) | $294.12M | $339.16M |
| Levered Free Cash Flow (TTM) | $231.29M | $96.00M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Doximity vs HealthEquity
| Metric | DOCS | HQY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 52.84 | 65.16 |
| Forward P/E | 51.95 | 24.19 |
| PEG Ratio | 51.95 | 24.19 |
| Price to Sales (TTM) | 19.64 | 6.21 |
| Price to Book (MRQ) | 11.30 | 3.64 |
| Market Capitalization | ||
| Market Capitalization | $11.58B | $7.72B |
| Enterprise Value | $10.75B | $8.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 18.23 | 6.87 |
| Enterprise to EBITDA | 44.08 | 21.05 |
| Risk & Other Metrics | ||
| Beta | 1.36 | 0.54 |
| Book Value per Share (MRQ) | $5.47 | $24.49 |
Financial Statements Comparison: Doximity vs HealthEquity
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DOCS | HQY |
|---|---|---|
| Revenue/Sales | $145.91M | $330.84M |
| Cost of Goods Sold | $15.79M | $106.53M |
| Gross Profit | $130.12M | $224.31M |
| Research & Development | $26.80M | $61.44M |
| Operating Income (EBIT) | $54.52M | $84.35M |
| EBITDA | $57.31M | $125.83M |
| Pre-Tax Income | $64.15M | $70.95M |
| Income Tax | $10.83M | $17.04M |
| Net Income (Profit) | $53.32M | $53.92M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DOCS | HQY |
|---|---|---|
| Cash & Equivalents | $209.61M | $287.89M |
| Total Current Assets | $1.09B | $472.80M |
| Total Current Liabilities | $156.26M | $116.34M |
| Long-Term Debt | $10.19M | $1.10B |
| Total Shareholders Equity | $1.08B | $2.12B |
| Retained Earnings | $186.89M | $218.35M |
| Property, Plant & Equipment | $8.89M | $41.45M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DOCS | HQY |
|---|---|---|
| Operating Cash Flow | $119.90M | $64.74M |
| Capital Expenditures | $0 | $-86,000 |
| Free Cash Flow | $96.98M | $48.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-26.79M | $-59.07M |
Short Interest & Institutional Ownership Analysis
| Metric | DOCS | HQY |
|---|---|---|
| Shares Short | 4.07M | 4.80M |
| Short Ratio | 2.65 | 5.51 |
| Short % of Float | 0.03% | 0.06% |
| Average Daily Volume (10 Day) | 2,390,453 | 981,810 |
| Average Daily Volume (90 Day) | 1,815,488 | 898,080 |
| Shares Outstanding | 188.88M | 86.54M |
| Float Shares | 133.18M | 84.86M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 0.96% | 1.07% |
Dividend Analysis & Yield Comparison: Doximity vs HealthEquity
| Metric | DOCS | HQY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |